<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05113576</url>
  </required_header>
  <id_info>
    <org_study_id>2021-293</org_study_id>
    <nct_id>NCT05113576</nct_id>
  </id_info>
  <brief_title>Combining Intratumoral Metabolic Heterogeneity and Dissemination Feature (Dmax) on 18F-FDG PET/CT Improves Prognosis Prediction in DLBCL</brief_title>
  <official_title>Combining Intratumoral Metabolic Heterogeneity and Dissemination Feature (Dmax) on 18F-FDG PET/CT Improves Prognosis Prediction in Diffuse Large B-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This retrospective study aimed to investigate the combined prognostic values of intratumoral&#xD;
      metabolic heterogeneity (MH), disseminate feature (Dmax) and total metabolic tumor volume&#xD;
      (TMTV) by 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography/computed tomography&#xD;
      ([18F]FDG PET/CT), and establish novel nomograms to improve prognosis prediction in diffuse&#xD;
      large B-cell lymphoma (DLBCL)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This retrospective study aimed to investigate the combined prognostic values of intratumoral&#xD;
      metabolic heterogeneity (MH), disseminate feature (Dmax) and total metabolic tumor volume&#xD;
      (TMTV) by 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography/computed tomography&#xD;
      ([18F]FDG PET/CT), and establish novel nomograms to improve prognosis prediction in diffuse&#xD;
      large B-cell lymphoma (DLBCL)&#xD;
&#xD;
      Patients would be retrospectively includedin this study.The inclusion criteria included (1)&#xD;
      pathologically proven DLBCL; (2) first-line treatment with R-CHOP or R-CHOP-like chemotherapy&#xD;
      including R-miniCHOP and R-ECHOP (rituximab, etoposide, prednisone, vincristine,&#xD;
      cyclophosphamide, and doxorubicin); (3) at least 2 evaluable hypermetabolic lesions on&#xD;
      PET/CT;(4) underwent pre-treatment [18F]FDG PET/CT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 10, 2013</start_date>
  <completion_date type="Actual">June 30, 2021</completion_date>
  <primary_completion_date type="Actual">May 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>the accuracy of prognosis prediction</measure>
    <time_frame>Through study completion, about 6 months</time_frame>
    <description>The accuracy of clinical model, PET models and combined model for prediction</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">132</enrollment>
  <condition>Diffuse Large B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>patient</arm_group_label>
    <description>patients with DLBCL</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        132 patients with DLBCL&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  (1) pathologically proven DLBCL, (2) first-line treatment with R-CHOP or R-CHOP-like&#xD;
             chemotherapy including R-miniCHOP and R-ECHOP (rituximab, etoposide, prednisone,&#xD;
             vincristine, cyclophosphamide, and doxorubicin),(3) at least 2 evaluable&#xD;
             hypermetabolic lesions on PET/CT, (4) underwent pre-treatment [18F]FDG PET/CT&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  (1) patients who had received surgical resection or other treatments before&#xD;
             chemotherapy, (2) patients who had coexistent central system lymphoma or other types&#xD;
             of malignancies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Nuclear Medicine and PET/CT Center, The Second Affiliated Hospital, School of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 2, 2021</study_first_submitted>
  <study_first_submitted_qc>November 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diffuse large B-cell lymphoma</keyword>
  <keyword>Positron emission tomography (PET)</keyword>
  <keyword>metabolic heterogeneity</keyword>
  <keyword>dissemination</keyword>
  <keyword>metabolic tumor volume</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

